Trial · NCT00654927
Results by group58
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 58
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Summary of Treatment Emergent Adverse Events (TEAE). | Fampridine-SR b.i.d. | Patients with Any AE | 176 | 99.4 | participants |
| Summary of Treatment Emergent Adverse Events (TEAE). | Fampridine-SR b.i.d. | Patients with Any Serious AE | 65 | 36.7 | participants |
| Summary of Treatment Emergent Adverse Events (TEAE). | Fampridine-SR b.i.d. | Patients with Any Possibly/Probably Related AE | 102 | 41.8 | participants |
| Summary of Treatment Emergent Adverse Events (TEAE). | Fampridine-SR b.i.d. | Patients withdrawn due to AE | 34 | 15.3 | participants |
| Summary of Treatment Emergent Adverse Events (TEAE). | Fampridine-SR b.i.d. | Patients who Died | 5 | 2.3 | participants |
| Summary of Treatment Emergent Adverse Events (TEAE). | Fampridine-SR b.i.d. | Maximum Severity/Patients with Any TEAE -Mild | 10 | 8.5 | participants |
| Summary of Treatment Emergent Adverse Events (TEAE). | Fampridine-SR b.i.d. | Maximum Severity/Patients with Any TEAE -Moderate | 66 | 38.4 | participants |
| Summary of Treatment Emergent Adverse Events (TEAE). | Fampridine-SR b.i.d. | Maximum Severity/Patients with Any TEAE -Severe | 100 | 47.5 | participants |
| Timed 25 Foot Walk (T25FW) | Fampridine-SR b.i.d. | (N=153) Baseline | 1.87 | Standard Deviation 0.94 | feet/second |
| Timed 25 Foot Walk (T25FW) | Fampridine-SR b.i.d. | (N=1) >0-8 Weeks | 1.98 | Standard Deviation NA | feet/second |
| Timed 25 Foot Walk (T25FW) | Fampridine-SR b.i.d. | (N=134) >8-16 Weeks | 2.09 | Standard Deviation 1.03 | feet/second |
| Timed 25 Foot Walk (T25FW) | Fampridine-SR b.i.d. | (N=141) >16-42 Weeks | 2.02 | Standard Deviation 1.04 | feet/second |
| Timed 25 Foot Walk (T25FW) | Fampridine-SR b.i.d. | (N=127) >42-68 Weeks | 1.82 | Standard Deviation 0.10 | feet/second |
| Timed 25 Foot Walk (T25FW) | Fampridine-SR b.i.d. | (N=111) >68-94 Weeks | 1.85 | Standard Deviation 1.05 | feet/second |
| Timed 25 Foot Walk (T25FW) | Fampridine-SR b.i.d. | (N=103) >94-120 Weeks | 1.77 | Standard Deviation 1.05 | feet/second |
| Timed 25 Foot Walk (T25FW) | Fampridine-SR b.i.d. | (N=92) >120-146 Weeks | 1.88 | Standard Deviation 0.10 | feet/second |
| Timed 25 Foot Walk (T25FW) | Fampridine-SR b.i.d. | (N=86) >146-172 Weeks | 1.84 | Standard Deviation 1.06 | feet/second |
| Timed 25 Foot Walk (T25FW) | Fampridine-SR b.i.d. | (N=76) >172-198 Weeks | 1.93 | Standard Deviation 1.34 | feet/second |
| Timed 25 Foot Walk (T25FW) | Fampridine-SR b.i.d. | (N=66) >198-224 Weeks | 1.82 | Standard Deviation 1.07 | feet/second |
| Timed 25 Foot Walk (T25FW) | Fampridine-SR b.i.d. | (N=56) >224-250 Weeks | 2.05 | Standard Deviation 1.16 | feet/second |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00654927/results